Summary
A 12-month prospective controlled study was conducted in 28 patients with acute osteoporotic spine fractures to evaluate and compare the effect of calcitonin treatment and cyclical hormone replacement therapy on forearm bone mineral content (BMC) and bone turnover. We established two treatment groups and a control group of women with postmenopausal osteoporosis (n=28). Group A (n=10) received 100 U of calcitonin by subcutaneous self-application on alternate days and oral calcium (Ca) for 6–8 weeks. Group B (n=10) received cyclical estrogen/gestagen replacement therapy over 12 months and oral calcium. The control group (n=8) received analgetic treatment and 500 mg Ca daily. BMC was measured by single photon absorptiometry (SPA) [1] with I 125 before and 6 and 12 months after the onset of the therapies. Ca, phosphorus (P), alkaline phosphatase, and 2-hour urinary OH-proline excretion were measured to classify bone turnover. One year after the onset of the two therapies, forearm BMC measured by SPA showed a significant increase in the group under hormone replacement therapy (P<0.025) as well as in the calcitonin group (P<0.05), although the latter underwent treatment only over a short period (6–8 weeks). In the same period, BMC decreased significantly in the control group (P<0.025). These results demonstrate that short-term calcitonin treatment over 6–8 weeks is as effective as long-term hormone replacement therapy, both therapies increasing forearm BMC measured by SPA.
Similar content being viewed by others
References
Cameron JR, Sorenson J (1963) Measurement of bone mineral in vivo: an improved method. Science 142:273–279
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Simson K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303
Milhaud G, Talbot JN, Coutris G (1975) Calcitonin treatment of postmenopausal osteoporosis. Evaluation of efficacy by principal components analysis. Biomedicine 22:223–232
Wallach S, Cohn SH, Atkins HL, Ellis KJ, Kohberger R, Aloia JF, Zanzi I (1977) Effects of salmon calcitonin on skeletal mass in osteoporosis. Cur Ther Res 22:556–572
Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a double-blind clinical study. Calcif Tissue Int 38:3–8
Serdengecti S, Serdengecti K, Derman U, Berkada B (1986) Salmon calcitonin in the treatment of bone metastasis. Int J Clin Pharm Res IV (2):151–155
Pencile A, Guidobono F, Sibilla V, Netti C (1984) Calcitonin-induced analgesia: role of monoaminergic systems. In: Cohn D, Fujita T, Pottis J Jr, Talmage R (eds) Endocrine control of bone and calcium metabolism. Elsevier Science Amsterdam, vol 8A
Lindsay R, Hart DM, Forrest C, Baird C (1980) Prevention of spinal osteoporosis in oophorectomized women. Lancet II:1151–1153
Christiansen C, Christensen MS, MacNair P, Hagen C, Stocklund K, Transbol I (1980) Prevention of postmenopausal bone loss: controlled study (2 years) in 315 normal females. Eur J Clin Invest 10:273–279
Mayo Medical Laboratories Communique (1984) 9:24
Gergely SM (1982) Österreichischer Ernährungsbericht:37–38
Kruse HP, Kuhlenkordt F (1980) Pathogenesis and natural course of primary osteoporosis. Lancet I:280–282
Agrawal R, Wallch S, Cohn SH, Tessier M, Verch R, Hussain M, Zanzi I (1981) Calcitonin treatment of osteoporosis. In: Pencile A (ed) Chemistry, physiology, pharmacology and clinical aspects. Calcitonin 1980. Excerpta Medica, Amsterdam, pp 237–246
Cohn SH, Dombrowski CS, Hauser W, Klopper J, Atkins HL (1971) Effects of porcine calcitonin in osteoporosis. J Clin Endocrinol Med 33:719–728
Nilas L, Christiansen C, Rodbro P (1984) Calcium supplementation and postmenopausal bone loss. Br Med J 289:1103–1106
MacIntyre I, Whitehead MI, Banks LM, Stevenson JC, Wimalawansa SJ, Healy MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet I:900–902
Christiansen C, Riss BJ, Podenphant J, Johansen JS (1987) Intranasal calcitonin in the treatment of postmenopausal osteoporosis In: Christiansen C, Johansen JS, Riss BJ (eds) Osteoporosis 1987. Viborg, Nørhaven A/S, pp 853–856
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet II:1481–1483
Parfitt AM (1983) Calcitonin in the pathogenesis and treatment of osteoporosis. Triangel 22, 2/3:91–102
Caniggia A, Lore F, Nuti R, Vattimo A (1981) In: Pencile A (ed) Chemistry, physiology, pharmacology and clinical aspects. Calcitonin 1980. Excerpta Medica, Amsterdam, pp 225–236
Conference Report (1987) Consensus Development Conference: Aalborg, Denmark. Prophylaxis and treatment of osteoporosis. Br Med J 295:914–915
Nachtigall LE, Nachtigall RH, Nachtigal RD, Beckmann EM (1979) Estrogen replacement therapy. A 10-year prospective study in relationship to osteoporosis. Obstet Gynecol 53:277–281
Christiansen C, Christensen MS, Transbol I (1981) Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet i:459–461
Hillyard CJ, Stevenson JC, MacIntyre I (1978) Relative deficiency of plasma calcitonin in normal women. Lancet i:961–962
Stevenson JC, Abeyasekera G, Hillyard CJ, Kheng Guek Phang, MacIntyre I (1981) Calcitonin and the calcium-regulatory hormones in postmenopausal women: effect of oestrogens. Lancet i:237
Sheetz KL, Baker M, Gallegos A, O'Malley BW, Haussler MR (1987) Bone-related cells in culture express putative estrogen receptor mRNA and 125 I-17-estradiol binding. J Bone Min Res 2 (suppl 1):237
Arntzenius AC, Kromhout D, Barth JD, Reiber JHC, Bruschke VG, Buis B, van Gent CM, Kempen Voogd N, Strikwerda S, van der Velde EA (1985) Diet, lipoproteins and the progression of coronary arteriosclerosis. The Leiden intervention trial. N Engl J Med 312:805–811
Poller L, Thomson JM, Coope J (1977) Conjugated equine oestrogens and blood clotting. A follow-up report. Br Med J 1:935–936
Hulka BS, Kaufmann DG, Fowler WC Jr, Grimson RC, Greenberg BG (1980) Predominance of early endometrial cancers after long-term estrogen use. JAMA 244:2419–2422
Whitehead MI, Townsend PT, Pryse-Davis J, Path FRC, Ryder TA, King JB (1981) Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305:1599–1605
Gambull RD, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM (1980) Use of progestagen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 55:732–738
Barrett-Connon E, Brown WV, Turner J, Austin M, Criqui MH (1979) Heart disease risk factor and hormone use in postmenopausal women. JAMA 241:2167–2169
Gonzales D, Ghiringhelli G, Mautalen C (1986) Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women. Calcif Tissue Int 38:71–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Resch, H., Pietschmann, P. & Willvonseder, R. Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures. Calcif Tissue Int 45, 209–213 (1989). https://doi.org/10.1007/BF02556039
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02556039